Executive record

Douglas Kerr

Public governance roles and source-backed Claims for this individual.

  • Executive

Alpha ID: alpha:person:douglas-kerr-dynVersion: public-0As of: 2026-09-28

Follow
More
Challenge a Claim

Identity

unclaimed

Evidence

corroborated

Evaluation

Unknown

Monitoring

Unknown

Authority

Unknown

Freshness

Observed 2026-09-28

Key Claims

Roles and authority

OrganizationRoleModuleGranted byFromTo
Dyne Therapeutics, Inc.Chief Medical OfficerExecutiveUnavailableUnavailableUnavailable

Exposure

Person-level exposure is withheld from public Executive records. Published exposure, where available, attaches to the relevant Enterprise record.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. DYN DEF 14A executive officers

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Dyne Therapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Medical Officer · Claim reviewed: May 16, 2026
    • Other Company Role: Douglas Kerr is also linked to BlueRock Therapeutics, LP, Trace Neuroscience, Inc., AAVantgarde Bio, s.r.l, and GenRab Therapeutics, Inc. as Board Member. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. Open source

    sec def 14a · Source published: Apr 23, 2026 · Retrieved: Sep 6, 2026

    Supports 1 claim
    • Professional Role: Chief Medical Officer at Dyne Therapeutics, Inc. · Claim reviewed: Sep 6, 2026

  3. DYN executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise reported in filings · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
    • Executive company: Executive at Dyne Therapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive function: Other Executive (OTHER_EXECUTIVE) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Medical Officer · Claim reviewed: May 16, 2026